Stay updated on Elranatamab vs Lenalidomide Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page.

Latest updates to the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page
- Check5 days agoChange DetectedRemoved the 'Multiple myeloma' topic and the 'MedlinePlus Genetics' related topics from the page. This reduces cross-linking to disease-specific topics and genetics resources on the study record.SummaryDifference0.0%

- Check12 days agoChange DetectedThe Study Details page now lists hundreds of new locations across multiple regions and adds related topics such as MedlinePlus Genetics. Recruitment-related information and contact details were updated.SummaryDifference7%

- Check19 days agoChange DetectedMagnetisMM-7 (NCT05317416) recruitment status updated to Active, not recruiting as of 2025-12-15, replacing the prior Recruiting status. Enrollment is not open at listed sites.SummaryDifference0.2%

- Check27 days agoChange DetectedNew study site added: Wroclaw, Poland (52-007). Recruitment status updated to Active, not recruiting as of 2025-12-04.SummaryDifference0.4%

- Check41 days agoChange DetectedThe study's recruitment locations have been updated to 217, with the removal of O'Brien Pharmacy (Mission, KS) and American Oncology Partners dba MidAmerica Cancer Care (Merriam, KS). Related topics now include Multiple Myeloma and MedlinePlus Genetics.SummaryDifference0.7%

- Check48 days agoChange DetectedStudy record status updated to Active, not recruiting. Revision dates 2025-11-11 and 2025-11-13 were added to the page history.SummaryDifference0.3%

Stay in the know with updates to Elranatamab vs Lenalidomide Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page.